PI
KROS icon

Putnam Investments’s Keros Therapeutics KROS Stock Holding History

Putnam Investments’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$516K Buy
12,978
+3,257
+34% +$102K ﹤0.01% 929
2023
Q3 		$310K Buy
9,721
+1,843
+23% +$68.8K ﹤0.01% 1065
2023
Q2 		$317K Sell
7,878
-238
-3% -$10.4K ﹤0.01% 1078
2023
Q1 		$347K Sell
8,116
-332
-4% -$16.8K ﹤0.01% 1051
2022
Q4 		$406K Buy
+8,448
New +$395K ﹤0.01% 984

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Putnam Investments's KROS Position: Q4 2023 in Review

Putnam Investments increased its Keros Therapeutics (KROS) stake by 34% in Q4 2023, buying an estimated $102K and bringing the position to 12,978 shares worth $516K. The position accounts for ﹤0.01% of the portfolio, ranked #929.

Putnam Investments first reported a position in KROS in Q4 2022 and has held it in 5 quarters since. 121 funds tracked by Wall St. Rank hold KROS as of Q4 2023.

  • Putnam Investments held 12,978 shares of Keros Therapeutics worth $516K as of Q4 2023.
  • Putnam Investments bought 3,257 Keros Therapeutics shares in Q4 2023, an estimated $102K.
  • Keros Therapeutics made up ﹤0.01% of Putnam Investments's portfolio in Q4 2023, its #929 holding.
  • Putnam Investments first reported a position in Keros Therapeutics in Q4 2022 and has held it in 5 quarters since.
  • 121 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.